Cited by 160Cardiovascular Syncope and Autonomic DisordersHeart Rate Variability and Autonomic ControlLong-Term Effects of COVID-19

The DOI matches its Crossref record; 77 of the 78 references it cites were found in a registry or an index; 7 of the 113 sources its claims cite were checked for support.

Postural Tachycardia Syndrome: Beyond Orthostatic Intolerance

Open access
Garland, Emily M., Celedonio, Jorge E., Raj, Satish R.·2015·Current Neurology and Neuroscience Reports

Abstract

Postural tachycardia syndrome (POTS) is a form of chronic orthostatic intolerance for which the hallmark physiological trait is an excessive increase in heart rate with assumption of upright posture. The orthostatic tachycardia occurs in the absence of orthostatic hypotension and is associated with a >6-month history of symptoms that are relieved by recumbence. The heart rate abnormality and orthostatic symptoms should not be caused by medications that impair autonomic regulation or by debilitating disorders that can cause tachycardia. POTS is a "final common pathway" for a number of overlapping pathophysiologies, including an autonomic neuropathy in the lower body, hypovolemia, elevated sympathetic tone, mast cell activation, deconditioning, and autoantibodies. Not only may patients be affected by more than one of these pathophysiologies but also the phenotype of POTS has similarities to a number of other disorders, e.g., chronic fatigue syndrome, Ehlers-Danlos syndrome, vasovagal syncope, and inappropriate sinus tachycardia. POTS can be treated with a combination of non-pharmacological approaches, a structured exercise training program, and often some pharmacological support.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11910-015-0583-8

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

82 Not checked yet · 7 Own interpretation · 2 Supported · 1 Partly supported · 1 Mixed support · accuracy not yet measured

Verify all 106 references — free account

Show all 39 claims

  • It may state two separate claims as one. 43
  • Probably not a substantial claim. 16
54 of 54
  • The paper relies on this without support.

    No drugs are approved by the US Food and Drug Administration for the treatment of POTS.

    “The US Food and Drug Administration has not approved any drugs for the treatment of POTS.”
  • The paper relies on this without support.

    Midodrine increases peripheral resistance in POTS by stimulating vasoconstriction.

    “Midodrine, a pro-drug of an α1-AR agonist, can increase peripheral resistance in POTS by stimulating vasoconstriction.”
  • The paper relies on this without support.

    Octreotide acts as a vasoconstrictor, primarily in the splanchnic circulation.

    “The somatostatin analog octreotide is a vasoconstrictor that mainly affects the splanchnic circulation.”
  • The paper relies on this without support.

    Ivabradine slows heart rate by inhibiting the funny channel current in the sinoatrial node without affecting blood pressure.

    “Ivabradine is a cardioselective agent that slows HR via inhibition of the funny channel current (If) in the cardiac sinoatrial node but does not affect BP.”
  • The paper relies on this without support.

    Ivabradine is approved for heart failure in the US and Europe and for angina in Europe.

    “Ivabradine is approved for the treatment of heart failure (US & Europe) and angina (Europe).”
  • The paper relies on this without support.

    Fludrocortisone acts on the mineralocorticoid receptor and quickly boosts sodium reabsorption in the kidney's distal tubules.

    “Fludrocortisone is a synthetic corticosteroid that preferentially binds to the mineralocorticoid receptor and acutely increases sodium reabsorption in the distal tubules of the kidney.”
6 of 6

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 78 references

Cited by

Sorted by citations

See all 160

Metadata

Authors
Garland, E. M., Celedonio, J. E., & Raj, S. R.
Affiliations
  • Vanderbilt University (US)
  • University of Calgary (CA)
Corresponding author
Garland, Emily M.
Venue
Current Neurology and Neuroscience Reports
Published
2015-07-22
Volume
15
Issue
9
Pages
60-60
ISSN
  • 1528-4042 (ISSN-L)
  • 1534-6293
OpenAlex
W1854421037
Cited by
160
References
78
Citations by year
2026: 5 · 2025: 12 · 2024: 13 · 2023: 7 · 2022: 25 · 2021: 20 · 2020: 21 · 2019: 16 · 2018: 19 · 2017: 15 · 2016: 5
FWCI
2.49
Type
journal article
Language
en
Open access
Locations
  • Current Neurology and Neuroscience Reports (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (UL1TR000445, TR000445)
  • National Heart, Lung, and Blood Institute (R01HL071784, P01HL056693, R01HL102387, P01 HL-56693)
  • National Institute of Neurological Disorders and Stroke (U54NS065736)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Syncope and Autonomic Disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
  • Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
Keywords
postural orthostatic tachycardia syndrome, orthostatic intolerance, orthostatic tachycardia, autonomic dysfunction, autonomic neuropathy, hypovolemia, sympathetic hyperactivity, mast cell activation, deconditioning, autoantibodies, chronic fatigue syndrome, Ehlers-Danlos syndrome, vasovagal syncope, inappropriate sinus tachycardia, exercise training, pharmacotherapy
MeSH terms
Chronic Disease, Heart Rate, Humans, Mast Cells, Posture, Orthostatic Intolerance, Postural Orthostatic Tachycardia Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review